United States: Federal Circuit Clarifies Calculation Of Patent Term Adjustment For Applications With Continued Examination Requests

Last Updated: January 25 2014
Article by Fabian M. Koenigbauer and Mark R. Shanks

In a recent ruling, the Federal Circuit clarified the scope of available Patent Term Adjustment (PTA) resulting from the U.S. Patent and Trademark Office's (PTO) failure to issue a patent within three years from the date the application was filed, for applications in which a request for continued examination (RCE) was made. Novartis AG v. Lee, 2013-1160, 2013-1179 (Fed. Cir. Jan. 15, 2014). Under the decision, PTA is not available for the period of prosecuting the RCE to allowance, but is available for the period from allowance to issuance.

Background on PTA and Recent Challenges to the PTO's Interpretation of B Delay

The term of a U.S. utility patent is 20 years measured from the filing date of the application. However, in practical terms, the patent application provides no benefit to the patentee until the day it issues as a patent from the PTO. Consequently, excessive delays at the PTO would significantly reduce the "effective" term of the patent. To avoid this result, Congress established a system of patent term adjustment that adds time to the end of a patent's life to offset certain kinds of delays encountered at the PTO.

Under this system, a patent is entitled to PTA based on delays attributable to the PTO. Specifically, the patent statute provides for PTA for three categories of patent office delays:

  1. "A delays" for failure of the PTO to act promptly, including its failure to issue a first Office Action within fourteen months from the filing date, or to respond to any applicant action within four months;
  2. "B delays" for failure of the PTO to issue a patent within three years of the filing date of the application (or entry of an international application into the National Stage); and
  3. "C delays" which accrue when an application is delayed due to a secrecy order, interference, derivation proceeding or appeal.

Notably, the statute provides certain exceptions to what would otherwise fall within B delay. For example, B delay does not include "any time consumed by continued examination of the application requested by the applicant." According to the PTO's rules, "time consumed by continued examination" is the period beginning when an RCE is filed and ending on the issue date of the patent.

Many patent owners have challenged the PTO's interpretation of what constitutes B delay in the situation where an RCE was filed more than three years after the application filing date. Exelixis, Inc. v. Kappos, 906 F. Supp. 2d 474 (E.D. Va. 2012) (Exelixis I) was the first case to address how to calculate B delay in such a situation. In Exelixis I, the court interpreted the statute's disallowance of RCE prosecution time to hinge upon the timing of when the RCE was filed. Specifically, the court held that the time spent prosecuting an RCE was only disallowed in calculating B delay when the RCE was filed within three years of the application filing date. If the RCE was filed after the three-year date, time spent prosecuting it was eligible for PTA on a day-for-day basis. Similarly, in Novartis A.G. v. Kappos, 904 F. Supp. 2d 58 (D. D.C. 2012), the District Court for the District of Columbia sided with the reasoning in Exelixis I and held that an RCE filed after the three-year date did not diminish B delay-related PTA.

However, in a subsequent case brought by Exelixis on the issue, (Exelixis, Inc. v. Kappos, 2013 WL 314754 (E.D. Va. Jan. 28, 2013) (Exelixis II)), the court took a contrary position and held that an RCE, no matter when it is filed, serves to toll B delay. Thus, under Exelixis II, time consumed by continued examination is always excludable from a PTA calculation. This decision created a split of authority within the Eastern District of Virginia on this issue. Since Exelixis I was decided, more than one hundred new PTA cases have been filed in the Eastern District of Virginia.

The Exelixis cases were consolidated on appeal, and the Novartis case was separately appealed. On November 5, 2013, the Federal Circuit heard oral arguments for all three cases. The Court subsequently issued a precedential opinion in Novartis and remanded the Exelixis cases in light of its Novartis decision.

The Federal Circuit Interprets B Delay to Exclude Time Spent Prosecuting RCE to Allowance Regardless of When RCE is Filed

The main issue in Novartis was the statutory interpretation of the B delay carve-out for "time consumed by continued examination." In addressing the issue, the Federal Circuit disposed of the Exelixis I interpretation of the statute, noting that such an interpretation "runs counter to the textual fact that there is no time-of-initiation restriction on the processes identified in the exclusions, including continued examination." Rather, the Court concluded that B delay "should be calculated by determining the length of time between application and patent issuance, then subtracting any continued examination time (and any other [exceptions]...) and determining the extent to which the result exceeds three years." Thus, "time spent in continued examination does not deplete the PTO's allotment of three years for application processing before a resulting patent has its term extended, no matter when continued examination begins."

As for the amount of time to be subtracted in determining B delay, the Federal Circuit further clarified that "time consumed by continued examination" does not include the time from allowance to issuance, as "such time is plainly attributable to the PTO." The Court reasoned that "examination" ends at allowance after prosecution on the merits has closed and no further examination on the merits occurs. Noting that the time from allowance to issuance undisputedly would count toward the PTO's three-year allotment in a case not involving a continued examination, the court found no basis for distinguishing a continued examination case. Thus, "'time consumed by continued examination,' 35 U.S.C. §154(b)(1)(B)(i), is the time up to allowance but not later, unless examination on the merits resumes."

Considerations for Patent Owners

First, since the period of time from allowance to issuance, if after three years from filing, is now eligible for PTA even when an RCE was filed, it may now be advantageous in some cases to delay paying the issue fee until close to the deadline in order to maximize the PTA.

Second, the Patent Office has not yet issued any internal guidance or revised its rules to account for the Novartis decision. Until the Office revises its procedures, it is unlikely that the PTA reported on the face of any patents that were prosecuted for more than three years and that included an RCE will be calculated correctly. However, since challenges to a PTA determination have to be filed within two months of the patent issuance (extendable by payment of fees for a total of seven months), correction of the mistake is only available for patents issued less than seven months ago. Accordingly, any patents issuing in the past seven months, as well as those that issue henceforth, should be reviewed for applicability of the change to the RCE exclusion mandated by the Novartis decision.

If you have any questions regarding PTA calculations, do not hesitate to contact our patent practitioners.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.